Company intelligence / Profile preview

이을바이오사이언스

Seocho-gu, Seoul, South Koreaibric.org ↗

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

The company is developing therapeutics using stem cells and stem cell-derived exosomes. They possess proprietary technology that can increase the secretion amount and change the composition of stem cell exosomes.

Modalities: Stem cellsstem cell-derived exosomes
Industry: Biotech

Drug pipeline

1 asset

Limelight CB-EVs

Commercial

Indications: Skin regeneration, Wrinkle improvement, Skin inflammation

Beyond the preview

Go deeper on 이을바이오사이언스.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 이을바이오사이언스.

Explore the full profile